BRPI0809238A2 - Derivados de piridazinonas úteis como inibidores de glican sintase - Google Patents

Derivados de piridazinonas úteis como inibidores de glican sintase Download PDF

Info

Publication number
BRPI0809238A2
BRPI0809238A2 BRPI0809238-9A BRPI0809238A BRPI0809238A2 BR PI0809238 A2 BRPI0809238 A2 BR PI0809238A2 BR PI0809238 A BRPI0809238 A BR PI0809238A BR PI0809238 A2 BRPI0809238 A2 BR PI0809238A2
Authority
BR
Brazil
Prior art keywords
alkyl
alkenyl
formula
group
original document
Prior art date
Application number
BRPI0809238-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Pauline C Ting
Robert G Aslanian
Jianhua Cao
David Won-Shik Kim
Rongze Kuang
Gang Zhou
Robert Jason Herr
Andrew John Zych
Jinhai Yang
Heping Wu
Nicolas Zorn
Original Assignee
Schering Corp
Albany Molecular Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Albany Molecular Res Inc filed Critical Schering Corp
Publication of BRPI0809238A2 publication Critical patent/BRPI0809238A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D515/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0809238-9A 2007-03-15 2008-03-12 Derivados de piridazinonas úteis como inibidores de glican sintase BRPI0809238A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91817107P 2007-03-15 2007-03-15
US60/918,171 2007-03-15
PCT/US2008/003257 WO2008115381A1 (en) 2007-03-15 2008-03-12 Pyridazinone derivatives useful as glucan synthase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0809238A2 true BRPI0809238A2 (pt) 2014-09-09

Family

ID=39525788

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809238-9A BRPI0809238A2 (pt) 2007-03-15 2008-03-12 Derivados de piridazinonas úteis como inibidores de glican sintase

Country Status (18)

Country Link
US (1) US8232274B2 (OSRAM)
EP (2) EP2586778A3 (OSRAM)
JP (3) JP5147866B2 (OSRAM)
KR (1) KR20100049500A (OSRAM)
CN (1) CN101730692A (OSRAM)
AR (1) AR065721A1 (OSRAM)
AU (1) AU2008227100B2 (OSRAM)
BR (1) BRPI0809238A2 (OSRAM)
CA (1) CA2680583A1 (OSRAM)
CL (1) CL2008000725A1 (OSRAM)
CO (1) CO6220966A2 (OSRAM)
EC (1) ECSP099634A (OSRAM)
IL (1) IL200906A0 (OSRAM)
MX (1) MX2009009948A (OSRAM)
PE (1) PE20081882A1 (OSRAM)
RU (1) RU2009137946A (OSRAM)
TW (1) TW200902516A (OSRAM)
WO (1) WO2008115381A1 (OSRAM)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0809193A2 (pt) 2007-03-15 2014-09-23 Novartis Ag Compostos orgânicos e seus usos
CN101668529A (zh) * 2007-03-15 2010-03-10 先灵公司 用作葡聚糖合成酶抑制剂的哌嗪取代的哒嗪酮衍生物
CN101801954B (zh) * 2007-09-20 2013-10-09 Irm责任有限公司 作为gpr119活性调节剂的化合物和组合物
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CA2814011A1 (en) * 2010-10-11 2012-04-19 Axikin Pharmaceuticals, Inc. Salts of arylsulfonamide ccr3 antagonists
FI20115234A0 (fi) 2011-03-08 2011-03-08 Biotie Therapies Corp Uusia pyridatsinoni- ja pyridoniyhdisteitä
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
WO2013073577A1 (ja) 2011-11-15 2013-05-23 アステラス製薬株式会社 ジヒドロキシ芳香族へテロ環化合物
WO2013155223A1 (en) * 2012-04-10 2013-10-17 The Regents Of The University Of California Compositions and methods for treating cancer
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
CN103664795B (zh) * 2012-09-06 2017-10-03 华东理工大学 哒嗪酮类化合物及其用途
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN104717924A (zh) 2012-10-05 2015-06-17 皇家飞利浦有限公司 用于提供增强的x射线图像的医学成像系统及方法
GB201222711D0 (en) * 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
CA2922567A1 (en) * 2013-08-26 2015-03-05 Purdue Pharma L.P. Azaspiro[4.5]decane derivatives and use thereof
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
JP2017517498A (ja) * 2014-04-24 2017-06-29 ヘキシマ リミテッド 薬剤および治療方法
EP3426029B1 (en) 2016-03-07 2023-08-30 AgroFresh Inc. Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
AU2018235937A1 (en) 2017-03-15 2019-09-19 Lunella Biotech, Inc. Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast
WO2018185013A1 (en) 2017-04-03 2018-10-11 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
CA3075727A1 (en) 2017-09-18 2019-03-21 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
CN109912476A (zh) * 2019-03-27 2019-06-21 南通宝凯化工有限公司 一种异丙氨基磺酰氯的生产工艺
TW202115042A (zh) * 2019-06-21 2021-04-16 大陸商江蘇豪森藥業集團有限公司 芳基磷氧化物類衍生物抑制劑、其製備方法和應用
WO2021113625A1 (en) * 2019-12-06 2021-06-10 Plexxikon Inc. Compounds and methods for cd73 modulation and indications therefor
MX2022013615A (es) 2020-04-30 2022-11-16 Gilead Sciences Inc Inhibidores de macrociclo de peptidilarginina deiminasas.
WO2023204124A1 (ja) * 2022-04-20 2023-10-26 日本曹達株式会社 ピリダジノン化合物並びに農園芸用殺菌剤、殺線虫剤、および医療用・動物用抗真菌剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS565734B2 (OSRAM) * 1973-02-28 1981-02-06
DE3048487A1 (de) * 1980-12-22 1982-07-29 Cassella Ag, 6000 Frankfurt Basisch substituierte pyridazine, ihre herstellung und ihre verwendung
ES540813A0 (es) 1985-02-28 1985-11-16 Abello Quimicos Farma Prod Sa Procedimiento de obtencion de 1,2-diazin-3 (2h)-onas con interes farmaceutico
JPH04235975A (ja) * 1991-01-21 1992-08-25 Nissan Chem Ind Ltd ピリダジノン誘導体および害虫防除剤
GB2256587A (en) 1991-06-11 1992-12-16 American Cyanamid Co Acetazolamide in sustained release form
HU227237B1 (en) * 2001-09-27 2010-12-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them
EP1479681A4 (en) 2002-01-31 2006-05-10 Daiichi Seiyaku Co IMIDAZO (1,2-a) pyridine
DE10216144A1 (de) * 2002-04-12 2003-11-06 Bayer Ag Substituierte 2-Phenyl-3(2H)-Pyridazinone
US20050209278A1 (en) * 2002-04-25 2005-09-22 Mcdonald Joseph J Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
UA77526C2 (en) * 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
ATE495155T1 (de) * 2003-11-19 2011-01-15 Array Biopharma Inc Heterocyclische inhibitoren von mek
US8076338B2 (en) * 2004-04-23 2011-12-13 Exelixis, Inc. Kinase modulators and methods of use
GB0524991D0 (en) * 2005-12-08 2006-01-18 Ge Healthcare Ltd Novel imaging agents for fibrosis
WO2007130383A2 (en) * 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
CN101668529A (zh) * 2007-03-15 2010-03-10 先灵公司 用作葡聚糖合成酶抑制剂的哌嗪取代的哒嗪酮衍生物

Also Published As

Publication number Publication date
MX2009009948A (es) 2009-09-24
ECSP099634A (es) 2009-10-30
AR065721A1 (es) 2009-06-24
PE20081882A1 (es) 2008-12-27
EP2586778A2 (en) 2013-05-01
EP2586778A3 (en) 2013-07-31
RU2009137946A (ru) 2011-04-20
AU2008227100B2 (en) 2014-01-09
EP2137179A1 (en) 2009-12-30
CN101730692A (zh) 2010-06-09
JP5147866B2 (ja) 2013-02-20
CO6220966A2 (es) 2010-11-19
AU2008227100A1 (en) 2008-09-25
US20090170861A1 (en) 2009-07-02
CA2680583A1 (en) 2008-09-25
EP2137179B1 (en) 2015-09-02
CL2008000725A1 (es) 2008-11-14
WO2008115381A1 (en) 2008-09-25
KR20100049500A (ko) 2010-05-12
JP2013014622A (ja) 2013-01-24
TW200902516A (en) 2009-01-16
JP2014051529A (ja) 2014-03-20
IL200906A0 (en) 2010-05-17
US8232274B2 (en) 2012-07-31
JP2010521461A (ja) 2010-06-24

Similar Documents

Publication Publication Date Title
BRPI0809238A2 (pt) Derivados de piridazinonas úteis como inibidores de glican sintase
US11111233B2 (en) Amino pyrimidine compound for inhibiting protein tyrosine kinase activity
EP2819996B1 (en) 6-alkynyl pyridines as smac mimetics
JP6298830B2 (ja) 治療用に活性なピラゾロ−ピリミジン誘導体
WO2008003770A1 (de) Phenyl substituierte heteroaryl-derivate und deren verwendung als antitumormittel
BR112015000790B1 (pt) Derivados de imidazopirazina como moduladores da atividade
WO2014076237A1 (en) Triazolopyrazine
BR112015010221B1 (pt) Inibidores de quinase alk, seus usos, composição farmacêutica, e método para fabricação de medicamento
EP2454253A1 (de) Aminopyridinderivate zur behandlung von tumoren und entzündungskrankheiten
EP1896472A1 (de) Alpha-carboline als cdk-1 inhibitoren
CN108473473A (zh) 用于抑制蛋白酪氨酸激酶活性的稠合嘧啶类化合物
AU2009279760B2 (en) Aurora kinase modulators and methods of use
DE102015012049A1 (de) Verbindungen als ASIC-Inhibitoren und deren Verwendungen
AU2014201996A1 (en) Pyridazinone derivatives useful as glucan synthase inhibitors
NZ720726B2 (en) Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.